Medical Devices - Blood Safety & Pathogen Reduction Technologies
Strategic Profile
The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The company operates on a B2B model targeting blood centers, hospitals, and healthcare providers, generating revenue through the sale of INTERCEPT Blood System products, service contracts, and licensing agreements.
Cyborg Score Rationale
Cerus has made roughly 20 million transfusible doses of INTERCEPT-treated blood components available to patients based on cumulative kits sold. The company has regulatory approval in major markets and growing market adoption, though faces product concentration risk and execution challenges in scaling new products like the INT200 platform.
Top Insights
Monopoly-like position in pathogen reduction for platelets/plasma with dual FDA-CE approval provides significant competitive moat
INT200 platform upgrade offers software/design enhancements while maintaining kit compatibility, positioning for geographic expansion
Heavy product concentration risk: company dependent on INTERCEPT adoption with emerging competitors developing alternative blood safety solutions
Company developing red blood cell (RBC) applications and growing fibrinogen complex business alongside core platelet/plasma products
Named Competitors
Blood Management Solutions — Competes in blood management products
Pathogen Inactivation Solutions — European blood processing and pathogen inactivation provider